T&R Biofab Co. Ltd - Asset Resilience Ratio
T&R Biofab Co. Ltd (246710) has an Asset Resilience Ratio of 0.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 246710 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how T&R Biofab Co. Ltd's Asset Resilience Ratio has changed over time. See 246710 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down T&R Biofab Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 246710 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩100.00 Million | 0.12% |
| Total Liquid Assets | ₩100.00 Million | 0.12% |
Asset Resilience Insights
- Limited Liquidity: T&R Biofab Co. Ltd maintains only 0.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
T&R Biofab Co. Ltd Industry Peers by Asset Resilience Ratio
Compare T&R Biofab Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for T&R Biofab Co. Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for T&R Biofab Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.55% | ₩17.28 Billion ≈ $11.71 Million |
₩98.45 Billion ≈ $66.72 Million |
-34.30pp |
| 2023-12-31 | 51.84% | ₩51.75 Billion ≈ $35.07 Million |
₩99.82 Billion ≈ $67.64 Million |
-1.39pp |
| 2022-12-31 | 53.23% | ₩40.42 Billion ≈ $27.39 Million |
₩75.94 Billion ≈ $51.46 Million |
-17.50pp |
| 2021-12-31 | 70.73% | ₩58.17 Billion ≈ $39.42 Million |
₩82.23 Billion ≈ $55.73 Million |
-5.30pp |
| 2020-12-31 | 76.03% | ₩36.88 Billion ≈ $24.99 Million |
₩48.51 Billion ≈ $32.87 Million |
-4.17pp |
| 2019-12-31 | 80.20% | ₩21.72 Billion ≈ $14.72 Million |
₩27.09 Billion ≈ $18.36 Million |
-11.94pp |
| 2018-12-31 | 92.13% | ₩28.66 Billion ≈ $19.42 Million |
₩31.10 Billion ≈ $21.08 Million |
+9.69pp |
| 2017-12-31 | 82.44% | ₩7.80 Billion ≈ $5.29 Million |
₩9.47 Billion ≈ $6.42 Million |
-1.57pp |
| 2016-12-31 | 84.01% | ₩8.06 Billion ≈ $5.46 Million |
₩9.59 Billion ≈ $6.50 Million |
-- |
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.